Literature DB >> 19169273

Epidermal growth factor-dependent cyclooxygenase-2 induction in gliomas requires protein kinase C-delta.

K Xu1, C-M Chang, H Gao, H-K G Shu.   

Abstract

Earlier, we showed that epidermal growth factor receptor (EGFR) signaling in human glioma cells increased cyclooxygenase-2 (COX-2) expression through p38-mitogen-activated protein kinase (MAPK)-dependent activation of the Sp family of transcription factors. Further mechanistic details of EGFR-dependent induction of COX-2 expression in glioma cells remained elusive. Protein kinase Cs (PKCs) comprise a family of serine-threonine kinases that are major mediators of signaling from receptor tyrosine kinases. Here, we report that PKC-delta, a novel PKC isoform, plays a role in EGF-dependent COX-2 induction in human glioma cells. Pharmacological inhibition and genetic silencing (through siRNA or dominant-negative expression) of PKC-delta confirm a role for this PKC isoform in EGF-dependent COX-2 induction. Overexpression of a functional PKC-delta enhanced COX-2 expression indicating that PKC-delta is not only necessary but also sufficient to regulate COX-2 levels. Inhibition of p38-MAPK pharmacologically or with siRNA further shows that p38-MAPK is required for activation of PKC-delta by EGF while inhibition of PKC-delta had no discernible effects on p38-MAPK activation. Finally, EGF stimulation promotes physical interactions between PKC-delta and Sp1 resulting in phosphorylation and nuclear localization of this transcription factor. These data provide the first evidence that PKC-delta is a critical link between p38-MAPK and Sp1-dependent COX-2 expression in human glioma cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19169273     DOI: 10.1038/onc.2008.500

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  8 in total

1.  Cyclooxygenase-2 is a novel transcriptional target of the nuclear EGFR-STAT3 and EGFRvIII-STAT3 signaling axes.

Authors:  Hui-Wen Lo; Xinyu Cao; Hu Zhu; Francis Ali-Osman
Journal:  Mol Cancer Res       Date:  2010-02-09       Impact factor: 5.852

2.  Cyclooxygenase-2 (COX-2) mediates arsenite inhibition of UVB-induced cellular apoptosis in mouse epidermal Cl41 cells.

Authors:  Z Zuo; W Ouyang; J Li; M Costa; C Huang
Journal:  Curr Cancer Drug Targets       Date:  2012-07       Impact factor: 3.428

3.  Multiple protein kinase pathways mediate amplified IL-6 release by human lung fibroblasts co-exposed to nickel and TLR-2 agonist, MALP-2.

Authors:  Fei Gao; Kelly A Brant; Rachel M Ward; Richard T Cattley; Aaron Barchowsky; James P Fabisiak
Journal:  Toxicol Appl Pharmacol       Date:  2010-06-17       Impact factor: 4.219

4.  Growth factor regulation of prostaglandin-endoperoxide synthase 2 (Ptgs2) expression in colonic mesenchymal stem cells.

Authors:  Monica R Walker; Sarah L Brown; Terrence E Riehl; William F Stenson; Thaddeus S Stappenbeck
Journal:  J Biol Chem       Date:  2009-12-14       Impact factor: 5.157

5.  Hesperidin alleviates rat postoperative ileus through anti-inflammation and stimulation of Ca(2+)-dependent myosin phosphorylation.

Authors:  Yong-Jian Xiong; Hong-Wei Chu; Yuan Lin; Fang Han; Ya-Chan Li; Ai-Guo Wang; Fu-Jin Wang; Da-Peng Chen; Jing-Yu Wang
Journal:  Acta Pharmacol Sin       Date:  2016-06-27       Impact factor: 6.150

6.  Protein kinase D mediates synergistic expression of COX-2 induced by TNF-{alpha} and bradykinin in human colonic myofibroblasts.

Authors:  James Yoo; Christine Chung; Lee Slice; James Sinnett-Smith; Enrique Rozengurt
Journal:  Am J Physiol Cell Physiol       Date:  2009-09-30       Impact factor: 4.249

7.  Transcription factor interactions mediate EGF-dependent COX-2 expression.

Authors:  Kaiming Xu; Hui-Kuo G Shu
Journal:  Mol Cancer Res       Date:  2013-05-01       Impact factor: 5.852

8.  COX-2 overexpression increases malignant potential of human glioma cells through Id1.

Authors:  Kaiming Xu; Lanfang Wang; Hui-Kuo G Shu
Journal:  Oncotarget       Date:  2014-03-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.